Vortioxetine as adjunctive therapy in the treatment of schizophrenia

Sofia Redaelli; Lilla Porffy; Ebenezer Oloyede; Olubanke Dzahini; Gabriella Lewis; Maria Lobo; Eromona Whiskey; Sukhi S Shergill

doi:10.1177/20451253221110014

Vortioxetine as adjunctive therapy in the treatment of schizophrenia

Ther Adv Psychopharmacol. 2022 Jul 5:12:20451253221110014. doi: 10.1177/20451253221110014. eCollection 2022.

Authors

Sofia Redaelli¹, Lilla Porffy¹, Ebenezer Oloyede¹, Olubanke Dzahini², Gabriella Lewis¹, Maria Lobo¹, Eromona Whiskey³, Sukhi S Shergill¹

Affiliations

¹ Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
² South London and Maudsley NHS Foundation Trust, London, UK.
³ Pharmacy Department, South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK.

Abstract

Background: The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking.

Objectives: Vortioxetine is a novel antidepressant that has been used as adjunctive therapy for the treatment of psychosis; however, its effectiveness in clinical practice is relatively unknown. In this study, we aimed to determine the potential clinical effectiveness and safety and tolerability of vortioxetine in psychosis.

Design: This is a non-interventional, retrospective study on the add-on use of vortioxetine in a group of people with schizophrenia-spectrum disorders in a large UK NHS mental health trust.

Methods: Clinical effectiveness of vortioxetine was retrospectively assessed through the Clinical Global Impression - Severity (CGI-S) scale at 3 months. Safety and tolerability were evaluated through treatment discontinuation rates at 3, 6, and 12 months, and clinical reasons were evaluated at the primary endpoint of 3 months.

Results: Data were available for 40 subjects with a diagnosis of schizophrenia or schizoaffective disorder-prescribed vortioxetine treatment; 30 (75%) remained on treatment at 3 months. At CGI-S assessment, 15 of the 35 evaluated subjects reported at least a 1-point improvement, from 5 at baseline to 4 after 3 months of treatment. Twenty-six (65%) remained on treatment at 1-year follow-up. The main reasons for those discontinuing treatment were inadequate response (10%) and manic switch (7.5%), while one subject refused treatment. Tolerability to treatment was good, and 36 subjects (90%) reported no adverse events specific to vortioxetine treatment.

Conclusion: Schizophrenia is a complex illness, and there is insufficient treatment response in many individuals. A significant proportion of whom may require adjunctive treatments depending on the nature of the residual symptoms. Vortioxetine could be a potentially safe and effective option in such people, but further controlled studies are required.

Keywords: discontinuation; effectiveness; psychosis; schizophrenia; tolerability; vortioxetine.

Grants and funding

G0901868/MRC_/Medical Research Council/United Kingdom